ADHANSIA XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adhansia Xr, and what generic alternatives are available?
Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.
This drug has thirty-three patent family members in seventeen countries.
The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adhansia Xr
A generic version of ADHANSIA XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
Summary for ADHANSIA XR
International Patents: | 33 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 22 |
Clinical Trials: | 2 |
Patent Applications: | 46 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ADHANSIA XR |
What excipients (inactive ingredients) are in ADHANSIA XR? | ADHANSIA XR excipients list |
DailyMed Link: | ADHANSIA XR at DailyMed |


Recent Clinical Trials for ADHANSIA XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Purdue Pharma LP | Phase 4 |
Pharmacology for ADHANSIA XR
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Anatomical Therapeutic Chemical (ATC) Classes for ADHANSIA XR
US Patents and Regulatory Information for ADHANSIA XR
ADHANSIA XR is protected by twelve US patents and one FDA Regulatory Exclusivity.
Patents protecting ADHANSIA XR
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting ADHANSIA XR
LABELING REVISIONS RELATED TO CLINICAL STUDIES
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-006 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-004 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-003 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADHANSIA XR
See the table below for patents covering ADHANSIA XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2015337779 | Methods and compositions particularly for treatment of attention deficit disorder | ⤷ Try a Trial |
South Korea | 20170115036 | 특히 주의력 결핍 장애의 치료를 위한 방법 및 조성물 (METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER) | ⤷ Try a Trial |
Brazil | 112017008993 | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |